Advanced searches left 3/3

Treatment of Cancer - DOAJ

Summarized by Plex Scholar
Last Updated: 18 April 2022

* If you want to update the article please login/register

Targeting TNFR2: A Novel Breakthrough in the Treatment of Cancer

Tumor necrosis factor receptor type II is present in many tumor cells and some immune cells, such as regulatory T cells and myeloid-derived suppressing cells, as well as myeloid-derived suppressing cells. We summarized the expression and function of TNFR2 within various immune cells, as well as the potential advantages and disadvantages of targeting TNFR2 in immunotherapy. Finally, the advantages and disadvantages of TNFR2 to treat tumor-related diseases are discussed, as well as the challenges that may be encountered during the clinical development and use of targeted anti-TNFR2 agonists and inhibitors are investigated.

Source link: https://doi.org/10.3389/fonc.2022.862154


Major Advances in the Treatment of Cancer What does a Non-Oncologist need to know?

This report summarizes the most significant developments in the field of multiple cancer therapy over the past four years, finding that it is impossible for the non-oncologist to keep up with the most recent advancements in the field of oncology. New therapies have emerged in other areas, such as the use of targeted therapies in hepatocellular carcinoma and renal cell carcinoma. Breast cancer, chronic myeloid leukemia, and others are among the newly emerging targeted therapies where resistance was previously observed with the existing targeted therapies has arisen in yet another group. The addition of chemotherapeutic agents has improved longevity in several types of cancer, including oxaliplatin in adjuvant chemotherapy of colon cancer, temozolamide in glioblastoma multiforme, and adjuvant chemotherapy in non-small cell lung cancer.

Source link: https://doaj.org/article/7582452bae814eae9427187d0de5d354


T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein

Abstract Background EMD 521873 is a fusion protein that binds specifically to the high-affinity IL-2 receptor, as well as an antibody that is specific for both single- and double-stranded DNA and is intended to facilitate tumor tissue enrichment. Both CD4 + and CD8+ T-cells were activated by strong stimulation of both CD4 + and CD8+ T-cells, as well as poor NK cell activation, according to PD data, which was analyzed during the first two treatment cycles. Conclusions The results support follow-up studies evaluating Selectikine's clinical safety for cancer patients with predominant T-cell and low NK cell activation.

Source link: https://doi.org/10.1186/1479-5876-11-5


Heat Shock Protein (HSP) peptide and HSP-based immunotherapies for the treatment of cancer

The 70 and 90 kDa thermogenic heat shock proteins with a molecular weight of about 70% and 90 kDa function as molecular chaperones that aid folding/unfolding and transport of proteins across membranes and prevent protein aggregation under environmental stress. Tumor cell proliferation, metastasis, and protection against apoptosis are among tumor cell precursors found in comparison to normal cells. HSP70 and Hsp90 antibodies in tumor cells are higher cytosolic HSP70 and Hsp90 levels, which are attributed to tumor cell proliferation, metastasis, and protection against apoptosis in comparison to normal cells.

Source link: https://doi.org/10.3389/fimmu.2016.00171


Nanogels as potential nanomedicine carrier for treatment of cancer: A mini review of the state of the art

However, there is urgent need for timely clinical evidence from nanogels in order to enable translation of the nanogel concept into a commercially useful therapeutic approach for cancer treatment. The present paper examines the use of extracellular pH targeting for nanogels, siRNA delivery, PEGylated nanogels, multi-responsive nanogels, and intracellular delivery of nanogels for enhanced cancer therapy.

Source link: https://doi.org/10.1016/j.jsps.2014.04.001


Demethylating Agents in the Treatment of Cancer

Gene silencing caused by insufficient DNA methylation can lead to tumorigenesis. Hence, drugs that inhibit or interfere with DNA methylation have been used to reactivate and cause silenced gene re-expression in malignancies. Also, we talk about some of the drawbacks in the use of azacitidine and decitabine in cancer therapy.

Source link: https://doi.org/10.3390/ph3072022


Radiolabelled Aptamers for Theranostic Treatment of Cancer

Metastatic disease linked to cancer accounts for the majority of mortality rates, so early detection of metastatic tumors can aid prognosis. However, a considerable number of patients will also be diagnosed with micrometastasis tumours, which are often missed, as conventional medical imaging techniques are unable to detect micrometastases due to a lack of specificity and sensitivity. Aptamers are a class of single-stranded RNA or DNA ligands with high specificity, binding affinity, and selectivity for a target, making them ideal for molecular biomarker imaging. To date, a number of aptamers related to cancer cell markers have been radiolabelled and characterized.

Source link: https://doi.org/10.3390/ph12010002


Comparative analysis of enoxaparin versus rivaroxaban in the treatment of cancer associated venous thromboembolism: experience from a tertiary care cancer centre

Methods We performed a retrospective review to determine the efficacy and safety profile of rivaroxaban versus enoxaparin in cancer patients after onset of symptomatic deep vein thrombosis or pulmonary embolism. DVT and PE were detected in both the enoxaparin arm and the 70 patients in the rivaroxaban arm, according to the study. Our findings revealed that there was no statistically significant difference between the incidence of VTE recurrence at 6 months between the enoxaparin and rivaroxaban arm. Although medical risk factors for VTE in cancer patients such as elevated platelet count, elevated leukocyte count, low hemoglobin level, elevated risk of gastrointestinal, genitour, and lung cancers were not found to be significantly related to the risk of VTE recurrence in cancer patients, no risk of VTE recurrence was determined to be significantly associated with VTE recurrence. Conclusion In our cancer patient population, we found that there was no significant difference between the efficacy and safety profile of enoxaparin and rivaroxaban.

Source link: https://doi.org/10.1186/s12959-020-00221-2


Recent Advances on Drug-Loaded Mesenchymal Stem Cells With Anti-neoplastic Agents for Targeted Treatment of Cancer

Mesenchymal stem cells, undifferentiated group of adult multipotent cells, have unique anti-tumor characteristics, making them a novel choice to treat cancers. MSCs are a favored drug delivery method because of their ability to be loaded with chemotherapeutic drugs and release them in the site of primary and metastatic neoplasms, making them a popular choice for targeted drug delivery procedures. Along with in vitro and in vitro preclinical findings of antineoplastic effects of primed MSCs for clinical prospection, it also addresses drug delivery and release procedures.

Source link: https://doi.org/10.3389/fbioe.2020.00748

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions